2017 - CIRTA
2- Nutrition Management and Total Parenteral Nutrition
18.9 - A clinical audit of growth and clinical outcome in very low birthweight babies at the Auckland City Hospital Neonatal Intensive Care Unit before and after the introduction of SMOFlipid
Presenter: Helen, Evans, Auckland, New Zealand
Authors: Nicole Hill, Barbara Cormack, Kim Herbison, Helen Evans, Frank Bloomfield
A clinical audit of growth and clinical outcome in very low birthweight babies at the Auckland City Hospital Neonatal Intensive Care Unit before and after the introduction of SMOFlipid
Nicole S. Hill1, Barbara E. Cormack2,3, Kim Herbison4, Helen M. Evans4, Frank H. Bloomfield2,3.
1Discipline of Nutrition, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand; 2National Women’s Health, Auckland City Hospital, Auckland, New Zealand; 3Liggins Institute, University of Auckland, Auckland, New Zealand; 4National Intestinal Failure Service, Auckland District Health Borad, Auckland, New Zealand
Introduction: Intestinal failure associated liver disease in very low birthweight (VLBW; birthweight <1,500 g) babies is associated with lipid emulsion use. Multicomponent lipid emulsions may reduce this risk. The aim of this audit was to determine whether a change from a purely soybean oil-based emulsion (Intralipid) to one containing soy, medium-chain triglycerides, olive oil and fish oil (SMOFlipid) would improve growth and clinical outcomes in VLBW babies born at Auckland City Hospital.
Method: Consecutively-born VLBW babies were identified from a prospectively-maintained database. Data were collected from electronic clinical records and are presented as mean (SD). Data were available for 105 babies who received Intralipid and 102 babies who received SMOFlipid.
Results: Change in Z-scores for weight, length and head circumference between birth and 28 days or discharge did not differ between cohorts. Significantly fewer babies in the SMOFlipid group developed any retinopathy of prematurity (59% vs. 39%, p=0.005) or intraventricular haemorrhage (15% vs. 27%, p=0.03) prior to discharge. Mean total bilirubin levels were similar between cohorts in weeks 1, 2 and 4 after birth, with a significant difference only observed in week 3 (46 (3–203) vs. 42 (1–158) µmol/L, p=0.04). However, repeated measures analyses indicated that both mean (p=0.01), minimum (p=0.03) and maximum (p=0.04) total bilirubin were significantly lower over the first four weeks of life collectively among babies who received SMOFlipid.
Conclusion: These data indicate that SMOFlipid may be a favourable alternative to traditional lipid emulsions in neonatal parenteral nutrition regimens. This evidence will be used to inform the guidelines produced by the New Zealand National Intestinal Failure Service.
You must be logged in to view recordings
By viewing the material on this site you understand and accept that:
- The opinions and statements expressed on this site reflect the views of the author or authors and do not necessarily reflect those of The Transplantation Society and/or its Sections.
- The hosting of material on The Transplantation Society site does not signify endorsement of this material by The Transplantation Society and/or its Sections.
- The material is solely for educational purposes for qualified health care professionals.
- The Transplantation Society and/or its Sections are not liable for any decision made or action taken based on the information contained in the material on this site.
- The information cannot be used as a substitute for professional care.
- The information does not represent a standard of care.
- No physician-patient relationship is being established.